Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent

Recruiting

Phase 2

RVP-001Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent

Sponsor:

Reveal Pharmaceuticals Inc.

Code:

NCT06322342

Conditions

Central Nervous System (CNS) Lesions

Brain Metastases

Brain Neoplasms

Brain Neoplasms, Benign

Brain Tumor, Primary

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

RVP-001

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-09-17. This information was provided to ClinicalTrials.gov by Reveal Pharmaceuticals Inc. on 2025-08-14.